Holen Sie sich die Stockscreener-App
21.25
3.90%
0.7928
Schlusskurs vom Vortag:
$20.46
Offen:
$20.71
24-Stunden-Volumen:
212.84K
Relative Volume:
0.32
Marktkapitalisierung:
$890.58M
Einnahmen:
$5.92M
Nettoeinkommen (Verlust:
$-75.79M
KGV:
-10.05
EPS:
-2.1141
Netto-Cashflow:
$-59.15M
1W Leistung:
-3.99%
1M Leistung:
+5.50%
6M Leistung:
+351.33%
1J Leistung:
+375.56%
1-Tages-Spanne:
$20.27
$21.33
1-Wochen-Bereich:
$20.00
$22.59
52-Wochen-Spanne:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
21.33 | 854.26M | 5.92M | -75.79M | -59.15M | -2.1141 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.53 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
488.90 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Hochstufung | Jefferies | Hold → Buy |
| 2026-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit - Law360
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 7,433 shares in 10b5-1 trade - Stock Titan
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (NASDAQ:BIOA) Shares Gap DownHere's Why - MarketBeat
Risk Analysis: How does BioAge Labs Inc perform in inflationary periods2025 Performance Recap & Community Driven Trade Alerts - baoquankhu1.vn
Investment Recap: How do insiders feel about BioAge Labs Inc2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn
BIOA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion - Yahoo Finance
Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of BioAge Labs (BIOA) with Outperform Recommendation - Nasdaq
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal - TipRanks
BioAge Labs (BIOA) Price Target Increased by 10.09% to 30.60 - Nasdaq
Oppenheimer initiates BioAge Labs stock coverage with outperform rating By Investing.com - Investing.com Canada
Oppenheimer initiates BioAge Labs stock coverage with outperform rating - Investing.com
Technical Analysis: Is BioAge Labs Inc backed by strong institutional buyingQuarterly Portfolio Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Fed Watch: Whats the beta of BioAge Labs Inc stock2025 Market Sentiment & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
BioAge Labs, Inc. (BIOA) Receives Buy Rating From Jefferies With Significant Upside Potential - 富途牛牛
Jefferies upgrades BioAge Labs stock rating on drug potential By Investing.com - Investing.com Nigeria
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Jefferies Upgrades BioAge Labs (BIOA) - Nasdaq
Jefferies upgrades BioAge Labs stock rating on drug potential - Investing.com
BIOA Should I Buy - Intellectia AI
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Down 16.3% in January - MarketBeat
Is BioAge Labs Inc.’s ROE strong enough2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - mfd.ru
Will BioAge Labs Inc. stock hit new highs in YEARQuarterly Portfolio Review & AI Forecasted Stock Moves - mfd.ru
Will BioAge Labs Inc. stock deliver long term returnsWatch List & Weekly Breakout Watchlists - mfd.ru
How BioAge Labs Inc. stock benefits from tech adoptionEarnings Trend Report & Real-Time Volume Triggers - mfd.ru
Whale Trades: What is Columbia Sportswear Companys P E ratio telling usJuly 2025 Analyst Calls & Expert-Curated Trade Recommendations - baoquankhu1.vn
Returns Recap: Is BioAge Labs Inc a good stock for dollar cost averagingJuly 2025 Technicals & Consistent Profit Trade Alerts - baoquankhu1.vn
Can BioAge Labs Inc. lead its sector in growthJuly 2025 Weekly Recap & Expert Verified Stock Movement Alerts - mfd.ru
BioAge Labs (NASDAQ:BIOA) Trading Down 5.6%Here's What Happened - MarketBeat
Can BioAge Labs Inc. stock hit analyst price targetsWeekly Trade Analysis & High Accuracy Swing Trade Signals - mfd.ru
S P Trends: Whats the beta of BioAge Labs Inc stockShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
BioAge Labs (BIOA) Price Target Increased by 127.08% to 27.80 - Nasdaq
Morgan Stanley Boosts Price Target on BioAge Labs to $23 From $12, Keeps Equalweight Rating - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Insider Sells $139,368.75 in Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen - MarketBeat
BioAge Labs (NASDAQ:BIOA) Trading 8% HigherHere's Why - MarketBeat
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential - Pharma Voice
BioAge Labs Completes $115 Million Upsized Public Offering - Global Legal Chronicle
Piper Sandler Initiates Coverage of BioAge Labs (BIOA) with Overweight Recommendation - Nasdaq
BioAge Labs (NASDAQ:BIOA) Shares Gap UpShould You Buy? - MarketBeat
Piper Sandler Initiates BioAge Labs at Overweight With $73 Price Target - marketscreener.com
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating - TipRanks
BioAge Labs stock initiated with Overweight rating by Piper Sandler - Investing.com UK
BioAge Labs (NASDAQ:BIOA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Fenwick Represents BioAge Labs in $115M Upsized Public Offering - fenwick.com
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Mar 02 '26 |
Sale |
20.30 |
7,433 |
150,890 |
0 |
| GOLDSTEIN DOV A MD | Chief Financial Officer |
Mar 01 '26 |
Option Exercise |
4.38 |
3,542 |
15,514 |
33,033 |
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):